Willuweit Katharina, Frey Alexandra, Bieniek Lisa, Heinold Andreas, Büchter Matthias, Horn Peter A, Wedemeyer Heiner, Herzer Kerstin
Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.
Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
BMC Gastroenterol. 2020 Aug 27;20(1):288. doi: 10.1186/s12876-020-01427-4.
The importance of donor-specific antibodies (DSA) after liver transplantation (LT) for graft and patient survival is an ongoing controversy. So far it has not been elucidated when and in how far DSA are harmful for graft and patient survival. Therefore, we had the aim to investigate the association of DSA with complications after LT.
Data of 430 LT recipients were collected and statistically analyzed. Detection of HLA antibodies (Ab) was performed by Luminex assay.
DSA were detected in 81 patients (18.8%). These were mainly HLA class II Ab (81.5%). HLA class II Ab show a higher MFI (median: 5.300) compared to HLA class I Ab (median: 2.300). There is no association between MFI levels and development of complications after LT. However, cirrhosis occurred significantly more often in DSA positive patients (18%) than in patients without detectable DSA (9%, P = 0.027). All DSA positive patients with cirrhosis of the graft showed HLA class II antibodies (OR: 3.028; 95% CI: 1.51-6.075; P = 0.002).
Occurrence of HLA class II DSA after LT is associated with graft cirrhosis and may indicate a higher risk to develop graft damage independent on MFI and requires an individualized risk management.
肝移植(LT)后供体特异性抗体(DSA)对移植物和患者生存的重要性一直存在争议。迄今为止,尚未阐明DSA何时以及在多大程度上对移植物和患者生存有害。因此,我们旨在研究DSA与肝移植后并发症之间的关联。
收集430例肝移植受者的数据并进行统计分析。通过Luminex检测法检测HLA抗体(Ab)。
在81例患者(18.8%)中检测到DSA。这些主要是HLA II类抗体(81.5%)。与HLA I类抗体(中位数:2300)相比,HLA II类抗体显示出更高的平均荧光强度(MFI)(中位数:5300)。MFI水平与肝移植后并发症的发生之间没有关联。然而,DSA阳性患者(18%)发生肝硬化的频率明显高于未检测到DSA的患者(9%,P = 0.027)。所有移植物发生肝硬化的DSA阳性患者均显示HLA II类抗体(比值比:3.028;95%置信区间:1.51 - 6.075;P = 0.002)。
肝移植后HLA II类DSA的出现与移植物肝硬化相关,可能表明发生移植物损伤的风险更高,与MFI无关,需要进行个体化风险管理。